Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Idacio, Hulio, Hyrimoz, Amjevita
Synonyms :
Adalimumab
Class :
Antipsoriatics, TNF Inhibitors, Monoclonal Antibodies
Brand Name :
Idacio, Hulio, Hyrimoz, Amjevita
Synonyms :
Adalimumab
Class :
Antipsoriatics, TNF Inhibitors, Monoclonal Antibodies
Dosage Forms & Strengths
Adult
Injection, prefilled glass syringe
10mg/0.1ml
10mg/0.2ml
20mg/0.2ml
20mg/0.4ml
40mg/0.4ml
40mg/0.8ml
80mg/0.8ml
Injection, prefilled syringe
20mg/0.4ml
40mg/0.4ml
40mg/0.8ml
80mg/0.8ml
Injection, vial
40mg/0.8ml
40
mg
Solution
Subcutaneous (SC)
every two weeks
40
mg
Solution
Subcutaneous (SC)
every 2 weeks
40
mg
Solution
Subcutaneous (SC)
every 2 weeks
80
mg
Solution
Subcutaneous (SC)
once a week
after 1 week, 4mg subcutaneous every 2 weeks
Subcutaneous (SC)
Initial dose: 160mg subcutaneously as four injections in each 40mg on day 1 or 40mg daily of two injections in 2 consecutive days, then 80mg subcutaneously two weeks later
Maintenance dose:
From week 4- administer 40mg subcutaneously every two weeks
Initial dose
:
160mg subcutaneously as four injections in 40mg each on day 1 or 80mg subcutaneously two weeks later
Maintenance dose:2 weeks later-40mg subcutaneously every two weeks
Initial dose: 160mg subcutaneously as four injections in 40mg each on day 1 or 80mg subcutaneously two weeks later
Maintenance dose:2 weeks later-40mg subcutaneously every two weeks
Injection, prefilled glass syringe
10mg/0.1ml
10mg/0.2ml
20mg/0.2ml
20mg/0.4ml
40mg/0.4ml
40mg/0.8ml
80mg/0.8ml
Injection, prefilled syringe
20mg/0.4ml
40mg/0.4ml
40mg/0.8ml
80mg/0.8ml
Injection, vial
40mg/0.8ml
Humira,cyltezo,hulio or amjevita:
<2 years or <10 kg:
Safety and efficacy not established
>2 years:
<15 kg: Dosage forms not available
15 to <30kg:20mg subcutaneous every two weeks
>30kg:40mg subcutaneous every two weeks
Abrilada, Hadlima:
<2 years or <10 kg:
Safety and efficacy not established
>2 years:
10 to <15 kgs:10mg subcutaneous every two weeks
15 to >30kgs: 20mg subcutaneous every two weeks
>30kgs: 40mg subcutaneous every two weeks
>6 years(17 to <40 kgs)
80mg subcutaneously on Day 1, then two weeks later, give 40mg
Maintenance:20mg subcutaneous every two weeks from week 4
>6 years(>40 kgs)
160mg subcutaneously on Day 1, then two weeks later give 40mg
Maintenance:20mg subcutaneous every two weeks from week 4
<5 years: Safety and efficacy not established
>5 years (20 to <40kgs):
Days 1-15:
Day 1:80 mg subcutaneous
Day 8: 40mg subcutaneous
Day 15: 40mg subcutaneous
Maintenance dose: From week 4
80mg subcutaneous every two weeks
20mg subcutaneously every week
may decrease the therapeutic effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
measles, mumps, rubella, and varicella vaccine, live (Rx)
may decrease the therapeutic effect of immunosuppressants
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
vaccinia immune globulin intravenous (Rx)
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect when combined
may decrease the therapeutic effect when combined
may decrease the therapeutic effect when combined
may decrease the therapeutic effect when combined
may decrease the therapeutic effect when combined
may affect the absorption of drugs when combined
may affect the absorption of drugs when combined
may affect the absorption of drugs when combined
may affect the absorption of drugs when combined
may affect the absorption of drugs when combined
may decrease the therapeutic effect of Fc Receptor-Binding agents
may diminish the immunosuppressive effect of each other when combined
measles, mumps, rubella, and varicella vaccine, live
may diminish the immunosuppressive effect of each other when combined
measles mumps and rubella vaccine, live
may diminish the immunosuppressive effect of each other when combined
may diminish the immunosuppressive effect of each other when combined
smallpox (vaccinia) vaccine, live
may diminish the immunosuppressive effect of each other when combined
human papillomavirus vaccine, nonavalent
may diminish the pharmacodynamic antagonistic effect of each other when combined
may increase the toxic effects of anti-neoplastic properties
may increase the immunosuppressive effect
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may increase the toxic effect
may diminish the serum concentration
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may diminish the serum concentration
pneumococcal vaccine polyvalent
the activity of pneumococcal vaccine polyvalent is reduced due to pharmacodynamic antagonism
pneumococcal vaccine 13-valent
adalimumab diminishes the efficacy of the 13-valent pneumococcal vaccine through pharmacodynamic antagonism
dengue vaccine efficacy will be reduced by adalimumab by immunosuppression
the peril or acuteness of adverse effects can be increased when adalimumab is combined with stepronin
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
the efficacy of the vaccine may be reduced
the risk of adverse effects can be increased
the rate of metabolism of cethromycin may be increased
the risk of adverse effects can be enhanced when adalimumab is administered with anthrax vaccine adsorbed
Adalimumab blocks TNF receptor interaction on cell surfaces to reduce inflammation and immune system overactivity in autoimmune diseases.
It is human monoclonal antibody targets TNF-alpha involved in inflammation.
Frequency defined:
>10%
Upper respiratory tract infection
Increased creatine phosphokinase
Headache
Injection site pain
Rash
Sinusitis
1-10%
Nausea
Urinary tract infection
Flulike syndrome
Back pain
Abdominal pain
Hematuria
Increased alkaline phosphatase
<1%
Allergic reactions
Hematologic disorder
Adalimumab decreases immune system function that increase risk of serious infections.
Patients with rheumatoid arthritis may have double the risk compared to the general population.
Contraindications:
Hypersensitivity
Cautions:
CHF
Malignancy
Demyelinating disorders
Drug-induced Lupus
Blood dyscrasias
Hepatic impairment
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Adalimumab binds to TNF-alpha that stop inflammation and immune responses with TNF receptors. TNF-alpha is produced with activated macrophages, monocytes, and T-cells.
Pharmacodynamics:
Adalimumab reduces inflammation to block pro-inflammatory pathways. It achieves beneficial results in the treatment of autoimmune and inflammatory diseases.
Pharmacokinetic:
Absorption:
Bioavailability up to 64%.
Distribution:
The volume of distribution is 4.7 to 6 L.
Excretion and elimination:
Half-life: 10 to 20 days
It is administered through subcutaneous route in the injection form.
Generic Name: Adalimumab
Why do we use Adalimumab?
Adalimumab is used in the treatment of rheumatoid arthritis and hidradenitis suppurativa.
It is indicated in treatment of ankylosing spondylitis, ulcerative colitis, and Crohn’s disease.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
